Therefore, treatment aiming at increasing CDH13 expression (in combination with administration of adiponectin receptor agonists) and/or selectively targeting the downstream signaling cascade, i.e., activation of the p38 MAPK γ isoforms, could be promising therapeutic targets in the treatment of IPF. Here, CDH13 is linked to idiopathic pulmonary fibrosis.